journal article·2026-05Open access

Context‐Dependent Role of GDF15: GDF15 + Tumor‐Associated Macrophages Suppress OSCC Progression by Enhancing Phagocytosis

Xinyu Zhou, Zhihang Zhou, Houyu Ju, Chaoyang Guo, Fangxing Zhu, Yiyi Zhang, Xu Chen, Tongchao Zhao, Laiping Zhong, Jingzhou Hu

Advanced Science· Volume 13· Issue 29

Abstract

ABSTRACT The growth differentiation factor 15 (GDF15) neutralizing antibody has shown to overcome resistance to immune checkpoint blockade (ICB) in various solid tumors. Though the therapeutic effect of GDF15 neutralizing antibody indicates a protumor role of secreted GDF15, the double‐edged effect of GDF15 has remained a mystery for a long. Herein, we performed single‐cell RNA‐sequencing on oral squamous cell carcinoma (OSCC) samples before and after ICB‐based therapy to explore the context‐dependent functions of GDF15 across distinct cellular subsets. It revealed that GDF15 + macrophages were enriched in ICB‐sensitive OSCCs after treatment and might participate in mediating tumor regression. Gdf15 fl/fl Lyz2 Cre mice illustrated that GDF15 deficiency in macrophages could accelerate tumor progression by suppressing the infiltration of CD8 + T cells. Mechanistically, macrophage‐intrinsic GDF15 could enhance the abilities to phagocyte tumor cells and to cross‐present antigens to CD8 + T cells. The functional enhancement of GDF15 was mediated through the upregulation of the NF‐κB signaling pathway in macrophages. Collectively, the cellular source of GDF15 could determine its effect on tumor progression, with GDF15 + macrophages exerting an antitumor role in OSCC, whereas secreted GDF15 exerting a protumor role. The latter could be neutralized by the GDF15 antibody. These findings would advance a comprehensive understanding of the double‐edged effect of GDF15.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: GDF15 and Related Biomarkers · Immune cells in cancer · IL-33, ST2, and ILC Pathways

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Oral and Maxillofacial‐Head and Neck Oncology Ninth People's Hospital College of Stomatology Shanghai Jiao Tong University School of Medicine Shanghai P. R. China

Shanghai Key Laboratory of Stomatology & Shanghai Research Institute of Stomatology & National Center for Stomatology National Clinical Research Center for Oral Diseases Shanghai P. R. China

Department of Stomatology Huashan Hospital Fudan University Shanghai P. R. China

Department of Oral Pathology Ninth People's Hospital College of Stomatology Shanghai Jiao Tong University School of Medicine Shanghai P. R. China

Department of Laboratory Medicine Shanghai Ninth People's Hospital Shanghai Jiao Tong University School of Medicine Shanghai P. R. China

Faculty of Medical Laboratory Science College of Health Science and Technology Shanghai Jiao Tong University School of Medicine Shanghai P. R. China

Funding

National Natural Science Foundation of China

References (42)

Show source-provided references
1. 10.1056/NEJMoa241543410.1056/NEJMoa2415434 ↗
2. 10.1038/s41467-022-33080-810.1038/s41467-022-33080-8 ↗
3. 10.1097/JS9.000000000000048910.1097/JS9.0000000000000489 ↗
4. 10.1097/JS9.000000000000189110.1097/JS9.0000000000001891 ↗
5. 10.1038/s41467-025-59004-w10.1038/s41467-025-59004-w ↗
6. 10.1038/s41467-024-46444-z10.1038/s41467-024-46444-z ↗
7. 10.1016/S1470-2045(13)70334-610.1016/S1470-2045(13)70334-6 ↗
8. 10.1038/s41586-024-08305-z10.1038/s41586-024-08305-z ↗
9. 10.1073/pnas.94.21.1151410.1073/pnas.94.21.11514 ↗
10. 10.1016/S0378-1119(97)00485-X10.1016/S0378-1119(97)00485-X ↗
11. 10.1002/jlb.65.1.210.1002/jlb.65.1.2 ↗
12. 10.1016/j.cytogfr.2021.11.00210.1016/j.cytogfr.2021.11.002 ↗
13. 10.1038/sj.bjc.660086910.1038/sj.bjc.6600869 ↗
14. 10.3390/ijms22201115110.3390/ijms222011151 ↗
15. 10.1186/s13046-018-0744-010.1186/s13046-018-0744-0 ↗
16. 10.1172/JCI9156110.1172/JCI91561 ↗
17. 10.1016/j.bcp.2012.10.00710.1016/j.bcp.2012.10.007 ↗
18. 10.1371/journal.pone.004383310.1371/journal.pone.0043833 ↗
19. 10.1053/j.gastro.2006.09.01510.1053/j.gastro.2006.09.015 ↗
20. 10.1016/S0026-895X(24)09260-510.1016/S0026-895X(24)09260-5 ↗
21. 10.1200/JCO.2012.43.882010.1200/JCO.2012.43.8820 ↗
22. Elevated Growth Differentiating Factor 15 Expression Predicts Long‐term Benefit of Docetaxel, Cisplatin and 5‐Fluorouracil Induction Chemotherapy in Patients With Oral Cancer
23. 10.1016/j.oraloncology.2008.07.01710.1016/j.oraloncology.2008.07.017 ↗
24. 10.1016/j.ejca.2008.10.02610.1016/j.ejca.2008.10.026 ↗
25. 10.1038/s41590-022-01398-610.1038/s41590-022-01398-6 ↗
26. 10.1038/nm.439310.1038/nm.4393 ↗
27. 10.1038/nm.439210.1038/nm.4392 ↗
28. 10.1038/nm.439410.1038/nm.4394 ↗
29. 10.1016/j.molmet.2024.10207010.1016/j.molmet.2024.102070 ↗
30. 10.1093/carcin/bgaa10310.1093/carcin/bgaa103 ↗
31. 10.1038/onc.2015.9510.1038/onc.2015.95 ↗
32. 10.1016/j.bbrc.2019.08.09010.1016/j.bbrc.2019.08.090 ↗
33. 10.1182/blood-2002-01-015110.1182/blood-2002-01-0151 ↗
34. 10.1016/j.febslet.2004.06.05610.1016/j.febslet.2004.06.056 ↗
35. 10.1038/s41413-021-00178-610.1038/s41413-021-00178-6 ↗
36. 10.1016/j.yexcr.2021.11252210.1016/j.yexcr.2021.112522 ↗
37. 10.1136/gutjnl-2022-32842810.1136/gutjnl-2022-328428 ↗
38. 10.1136/jitc-2021-00278710.1136/jitc-2021-002787 ↗
39. 10.1186/s12974-025-03369-810.1186/s12974-025-03369-8 ↗
40. 10.1016/j.canlet.2023.21618410.1016/j.canlet.2023.216184 ↗
41. Ponsegromab for the Treatment of Cancer Cachexia
42. 10.1158/1078-0432.CCR-23-163110.1158/1078-0432.CCR-23-1631 ↗